Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 33, 127725
Abstract
No abstract availableKeywords
Funding Information
- Chinese Academy of Medical Sciences
This publication has 14 references indexed in Scilit:
- KinMap: a web-based tool for interactive navigation through human kinome dataBMC Bioinformatics, 2017
- Targeting CDK4 and CDK6: From Discovery to TherapyCancer Discovery, 2016
- Epidemiology of pancreatic cancerWorld Journal of Gastroenterology, 2016
- Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic AdenocarcinomaJAMA, 2008
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007
- Three Mechanistically Distinct Kinase Assays Compared: Measurement of Intrinsic ATPase Activity Identified the Most Comprehensive Set of ITK InhibitorsSLAS Discovery, 2007
- Adjuvant Radiotherapy and 5-Fluorouracil After Curative Resection of Cancer of the Pancreas and Periampullary RegionAnnals of Surgery, 1999
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Postoperative Adjuvant Chemoradiation Improves SurvivalAnnals of Surgery, 1997
- Cancer Cell CyclesScience, 1996